Objective To study the glucagon-like peptide -1 (GLP-1) receptor agonist clinical efficacy in patients with type 2 diabetes.Methods June 2008~June 2009 was diagnosed with type 2 diabetes in 54 patients for the study, and were randomly divided into two groups, the control group were treated with oral medications metformin, the test group of patients affected by the addition of GLP-1 agonist treatment.Results The experimental group in triglycerides, LDL, total cholesterol, transaminases, apolipoprotein -2 aspect compared with the control group, the experimental group was significantly lower, but little change in the control group, a statisticaly significant difference between groups (P<0.05); overal patient outcomes after the experimental group Mann-Whitney U rank sum test was significantly better than the control group, there was a significant difference statisticaly significant (P<0.01).Conclusion The clinical efficacy of GLP-1 receptor agonists in patients with type 2 diabetes significantly help to reduce the incidence of complications. worth in the clinical application and promotion.%目的 研究胰高血糖素样肽-1(GLP-1)受体激动剂对2型糖尿病患者的临床疗效.方法 选取2008年6月~2009年6月被确诊为2型糖尿病的54例患者为研究对象,并随机分为两组,对照组患者给予口服二甲双胍药物,试验组患者加用GLP-1受体激动剂治疗.结果试验组在甘油三酯、低密度脂蛋白、总胆固醇、转氨酶、载脂蛋白-2方面与对照组相比,试验组明显降低,而对照组变化不大,组间差异具有统计学意义(P<0.05);试验组患者整体治疗效果经Mann-Whitney U秩和检验后显著性优于对照组,存在显著性差异,具有统计学意义(P<0.01).结论 GLP-1受体激动剂对2型糖尿病患者的临床疗效显著,有利于减少并发症的发生.
展开▼
